Goldman Sachs Group Inc Buys 500,000 Shares of Attovia Therapeutics (NASDAQ:ATTO) Stock

Attovia Therapeutics, Inc. (NASDAQ:ATTO) major shareholder Goldman Sachs Group Inc acquired 500,000 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average cost of $17.00 per share, with a total value of $8,500,000.00. Following the completion of the purchase, the insider owned 3,020,632 shares of the company’s stock, valued at $51,350,744. This trade represents a 19.84% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Goldman Sachs Group Inc also recently made the following trade(s):

• On Wednesday, August 5th, Goldman Sachs Group Inc sold 105,807 shares of Attovia Therapeutics stock. The shares were sold at an average price of $21.28, for a total transaction of $2,251,572.96.
• On Wednesday, August 5th, Goldman Sachs Group Inc purchased 85,000 shares of Attovia Therapeutics stock. The stock was acquired at an average price of $21.00 per share, with a total value of $1,785,000.00.

Attovia Therapeutics Stock Performance

Shares of ATTO opened at $19.86 on Friday. Attovia Therapeutics, Inc. has a fifty-two week low of $16.15 and a fifty-two week high of $22.79.

Institutional Trading of Attovia Therapeutics

A hedge fund recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. raised its stake in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent reporting period.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.